Correctional Services - Medication Review Committee - Administration of Psychotropic Medication to an Incarcerated Individual
HB279 creates a new Section 9-619 in the Correctional Services Article to govern when psychotropic medication may be administered to an incarcerated individual who refuses it in a State correctional mental health care facility. The bill generally prohibits forced administration of psychotropic medication unless there is an emergency involving imminent danger to self or others, or unless a multi-member medication review committee determines that nonemergency involuntary medication is clinically justified and necessary under specified standards.
The bill sets out a detailed procedural framework for these decisions. It defines the committee’s membership, requires notice to the incarcerated individual and relevant representatives, provides for an impartial lay advisor, allows the individual to attend part of the meeting and present evidence, and requires a written report from the treating psychiatric provider. It also creates administrative review rights through the Office of Administrative Hearings and further appeal to circuit court, limits approvals to 90 days, requires periodic renewal review, and mandates ongoing documentation, reporting, and safeguards regarding restraints, seclusion, and use of statements made during the process.
HB279 would add a new statutory process in Maryland law for nonemergency involuntary psychotropic medication in State correctional mental health care facilities, primarily affecting the Department of Public Safety and Correctional Services, correctional mental health providers, incarcerated individuals, and the Office of Administrative Hearings. It establishes new duties for treating psychiatrists or psychiatric nurse practitioners, creates a medication review committee structure, and adds reporting obligations to the Department and the Maryland Department of Health. The bill also amends the legal rights and procedural protections available to incarcerated individuals in this setting, including notice, advocacy assistance, administrative appeal, and limits on the use of certain statements.
The bill appears to have been viewed favorably overall, with no recorded opposition in the available vote history. It passed third reading unanimously in the House, 126-0, suggesting broad support for the measure’s procedural safeguards and clinical oversight framework. The bill was reported favorably with amendments, indicating some refinement during committee consideration, though no committee transcript is available to show detailed debate.
The main policy tension in HB279 is between correctional mental health treatment authority and the rights of incarcerated individuals to refuse medication. The bill addresses concerns about forced psychotropic medication by requiring clinical findings, committee review, notice, advocacy assistance, and appeal rights, while also preserving an emergency exception for imminent danger. Potential points of contention include the scope of involuntary treatment authority, the adequacy of due process protections, the composition and impartiality of the review committee, and the balance between institutional safety and individual autonomy. The reporting and restraint-related provisions also suggest concern about oversight and humane treatment in correctional mental health settings.